Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds

BACKGROUND: Tafenoquine (TQ) is an 8-aminoquinoline (8AQ) that has been tested in several Phase II and Phase III clinical studies and is currently in late stage development as an anti-malarial prophylactic agent. NPC-1161B is a promising 8AQ in late preclinical development. It has recently been repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcsisin, Sean R, Sousa, Jason C, Reichard, Gregory A, Caridha, Diana, Zeng, Qiang, Roncal, Norma, McNulty, Ronan, Careagabarja, Julio, Sciotti, Richard J, Bennett, Jason W, Zottig, Victor E, Deye, Gregory, Li, Qigui, Read, Lisa, Hickman, Mark, Nanayakkara, N P Dhammika, Walker, Larry A, Smith, Bryan, Melendez, Victor, Pybus, Brandon S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893421/
https://www.ncbi.nlm.nih.gov/pubmed/24386891
http://dx.doi.org/10.1186/1475-2875-13-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893421/
https://www.ncbi.nlm.nih.gov/pubmed/24386891
http://dx.doi.org/10.1186/1475-2875-13-2

Ejemplares similares